Biotech | April 22, 2022
Terran Biosciences announces licensing deal with Sanofi
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
U GRO Capital is a listed MSME lending fintech platform
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
Subscribe To Our Newsletter & Stay Updated
